These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

626 related articles for article (PubMed ID: 33742189)

  • 1. Resistance to second-generation androgen receptor antagonists in prostate cancer.
    Schmidt KT; Huitema ADR; Chau CH; Figg WD
    Nat Rev Urol; 2021 Apr; 18(4):209-226. PubMed ID: 33742189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Second-Generation Androgen Receptor Antagonists as Hormonal Therapeutics for Three Forms of Prostate Cancer.
    Rajaram P; Rivera A; Muthima K; Olveda N; Muchalski H; Chen QH
    Molecules; 2020 May; 25(10):. PubMed ID: 32456317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen Receptor Inhibitors in Patients With Nonmetastatic Castration-Resistant Prostate Cancer.
    George DJ; Morgans AK; Constantinovici N; Khan N; Khan J; Chen G; Hlebec V; Shore ND
    JAMA Netw Open; 2024 Aug; 7(8):e2429783. PubMed ID: 39190308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis.
    Mori K; Mostafaei H; Pradere B; Motlagh RS; Quhal F; Laukhtina E; Schuettfort VM; Abufaraj M; Karakiewicz PI; Kimura T; Egawa S; Shariat SF
    Int J Clin Oncol; 2020 Nov; 25(11):1892-1900. PubMed ID: 32924096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination therapy with androgen receptor N-terminal domain antagonist EPI-7170 and enzalutamide yields synergistic activity in AR-V7-positive prostate cancer.
    Hirayama Y; Tam T; Jian K; Andersen RJ; Sadar MD
    Mol Oncol; 2020 Oct; 14(10):2455-2470. PubMed ID: 32734688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvement in overall survival with Apalutamide, Darolutamide and Enzalutamide in patients with non-metastatic castration-resistant prostate cancer.
    Swami U; Agarwal N
    Cancer Treat Res Commun; 2020; 25():100205. PubMed ID: 32822968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacy of apalutamide darolutamide and enzalutamide for treatment of non-metastatic castrate-resistant prostate cancer: A systematic review and network meta-analysis.
    Kumar J; Jazayeri SB; Gautam S; Norez D; Alam MU; Tanneru K; Bazargani S; Costa J; Bandyk M; Ganapathi HP; Koochekpour S; Balaji KC
    Urol Oncol; 2020 Nov; 38(11):826-834. PubMed ID: 32605736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A meta-analysis on overall survival and safety outcomes in patients with nonmetastatic castration-resistant prostate cancer treated with novel hormonal agents.
    Rizzo A; Oderda M; Mollica V; Merler S; Morelli F; Fragomeno B; Taveri E; Sorgentoni G; Santoni M; Massari F
    Anticancer Drugs; 2022 Jan; 33(1):e43-e51. PubMed ID: 34387593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment and trials in non-metastatic castration-resistant prostate cancer.
    Lokeshwar SD; Klaassen Z; Saad F
    Nat Rev Urol; 2021 Jul; 18(7):433-442. PubMed ID: 34002069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SEOM clinical guidelines for the treatment of advanced prostate cancer (2020).
    González Del Alba A; Méndez-Vidal MJ; Vazquez S; Castro E; Climent MA; Gallardo E; Gonzalez-Billalabeitia E; Lorente D; Maroto JP; Arranz JA
    Clin Transl Oncol; 2021 May; 23(5):969-979. PubMed ID: 33625671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-23 Represses the Level of Cell Senescence Induced by the Androgen Receptor Antagonists Enzalutamide and Darolutamide in Castration-Resistant Prostate Cancer Cells.
    Gupta S; Pungsrinont T; Ženata O; Neubert L; Vrzal R; Baniahmad A
    Horm Cancer; 2020 Aug; 11(3-4):182-190. PubMed ID: 32562083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world burden of adverse events for apalutamide- or enzalutamide-treated non-metastatic castration-resistant prostate cancer patients in the United States.
    Hussain A; Jiang S; Varghese D; Appukkuttan S; Kebede N; Gnanasakthy K; Macahilig C; Waldeck R; Corman S
    BMC Cancer; 2022 Mar; 22(1):304. PubMed ID: 35317768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combining prostate cancer radiotherapy with therapies targeting the androgen receptor axis.
    Ghashghaei M; Kucharczyk M; Elakshar S; Muanza T; Niazi T
    Curr Oncol; 2019 Oct; 26(5):e640-e650. PubMed ID: 31708657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of Fall and Fracture Risk Among Men With Prostate Cancer Treated With Androgen Receptor Inhibitors: A Systematic Review and Meta-analysis.
    Myint ZW; Momo HD; Otto DE; Yan D; Wang P; Kolesar JM
    JAMA Netw Open; 2020 Nov; 3(11):e2025826. PubMed ID: 33201234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent Advances in Prostate Cancer Treatment and Drug Discovery.
    Nevedomskaya E; Baumgart SJ; Haendler B
    Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29734647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perspectives on the current and emerging chemical androgen receptor antagonists for the treatment of prostate cancer.
    Dellis AE; Papatsoris AG
    Expert Opin Pharmacother; 2019 Feb; 20(2):163-172. PubMed ID: 30462924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel and next-generation androgen receptor-directed therapies for prostate cancer: Beyond abiraterone and enzalutamide.
    Bambury RM; Rathkopf DE
    Urol Oncol; 2016 Aug; 34(8):348-55. PubMed ID: 26162486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Outcomes and Risk Stratification in Patients With Metastatic Hormone-Sensitive Prostate Cancer Treated With New-Generation Androgen Receptor Signaling Inhibitors.
    Suzuki K; Shiraishi Y; Furukawa J; Okamura Y; Bando Y; Hara T; Okada K; Terakawa T; Hyodo Y; Chiba K; Teishima J; Nakano Y; Miyake H
    Clin Genitourin Cancer; 2024 Oct; 22(5):102140. PubMed ID: 39018723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Warning against second-generation antiandrogen for metastatic castration sensitive prostate cancer.
    Inoue T; Sasaki T; Kato M; Masui S; Nishikawa K
    BJU Int; 2021 Nov; 128(5):550. PubMed ID: 34333840
    [No Abstract]   [Full Text] [Related]  

  • 20. Combination therapy with novel androgen receptor antagonists and statin for castration-resistant prostate cancer.
    Nakayama H; Sekine Y; Oka D; Miyazawa Y; Arai S; Koike H; Matsui H; Shibata Y; Suzuki K
    Prostate; 2022 Feb; 82(3):314-322. PubMed ID: 34843630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.